From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

Post-transplantation cyclophosphamide vs tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation

Last Updated: Thursday, September 15, 2022

A single-center study analyzed the outcomes of 964 patients who received tacrolimus and methotrexate or post-transplantation cyclophosphamide (PTCy) for GvHD prophylaxis. It found that PTCy was associated with significantly improved relapse-free survival and lower risk of chronic GvHD. 

Transplantation and Cellular Therapy 
Advertisement
News & Literature Highlights
Advertisement
Advertisement